Michel Delforge
Overview
Explore the profile of Michel Delforge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
6094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrot A, Facon T, Plesner T, Usmani S, Kumar S, Bahlis N, et al.
Eur J Haematol
. 2025 Feb;
PMID: 39952901
Objectives: This final post hoc analysis evaluated patient-reported outcomes from the Phase 3 MAIA study of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) after median 64.5-month follow-up...
2.
Delforge B, Mahieu E, Dendooven A, Delforge M, Salembier A, Claeys L, et al.
Acta Clin Belg
. 2025 Feb;
:1-4.
PMID: 39924927
Objectives: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a subtype of monoclonal gammopathy of renal significance (MGRS). PGNMID can present with insidious, slowly progressing kidney damage to overt nephrotic...
3.
Hultcrantz M, Kleinman D, Vij R, Escalante F, Delforge M, Kotowsky N, et al.
Haematologica
. 2024 Oct;
110(3):753-757.
PMID: 39415693
No abstract available.
4.
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al.
Leukemia
. 2024 Sep;
38(12):2554-2560.
PMID: 39322709
Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of...
5.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, et al.
Future Oncol
. 2024 Sep;
20(38):3043-3063.
PMID: 39287147
What Is This Summary About?: This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called...
6.
Vanthienen W, Fernandez-Garcia J, Baietti M, Claeys E, Van Leemputte F, Nguyen L, et al.
Front Oncol
. 2024 Sep;
14:1411983.
PMID: 39239276
Many cancer cells share with yeast a preference for fermentation over respiration, which is associated with overactive glucose uptake and breakdown, a phenomenon called the Warburg effect in cancer cells....
7.
Nanni C, Deroose C, Balogova S, Lapa C, Withofs N, Subesinghe M, et al.
Eur J Nucl Med Mol Imaging
. 2024 Aug;
52(1):171-192.
PMID: 39207486
We provide updated guidance and standards for the indication, acquisition, and interpretation of [F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical...
8.
Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka A, Manier S, et al.
Blood
. 2024 Aug;
144(23):2389-2401.
PMID: 39197072
Outcomes are poor in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized...
9.
Nevejan L, Perkins M, Vercammen M, Vanhove T, Delforge M, Bossuyt X
Clin Chem
. 2024 Aug;
70(10):1291-1293.
PMID: 39162305
No abstract available.
10.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al.
Lancet Oncol
. 2024 Jun;
25(8):1003-1014.
PMID: 38889735
Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone...